DrugBiological
Antibodies, Monoclonal clinical trials
- studies test it
- 10
- open now
- 3
- in phase 3
- 2
- first study started
- 2002
Keep track of what changes. Save the Antibodies, Monoclonal studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2002 (1)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 5
- Phase 3
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 5
Immunocore Ltd (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1) · GlaxoSmithKline (1) · Light Chain Bioscience - Novimmune SA (1) · Dana-Farber Cancer Institute (1) · Johns Hopkins University (1) · University of Oxford (1) · Fujian Cancer Hospital (1)
Often tested with
Tested in the same studies.
Tacrolimus (2) · Brenetafusp (1) · Pembrolizumab (1) · Tebentafusp (1) · Bevacizumab (1) · Rituximab (1) · Nirmatrelvir and ritonavir drug combination (1) · Nitazoxanide (1)
Studies
Open first, then newest update. How each study uses Antibodies, Monoclonal is read from its arms, and is right about nine times in ten.
Testing it · 10
- Human Penile AllotransplantationRecruitingPhase 2/3Johns Hopkins UniversityNCT02395497Written as Monoclonal Antibody (Humanized Anti-CD52)
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)RecruitingPhase 2University of OxfordNCT05041907Written as Monoclonal antibodies
- Nituzumab Plus Serplulimab Combined With SBRT in Cervical CancerRecruitingPhase 2Fujian Cancer HospitalNCT06455072Written as Nituzumab
- Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsActive, not recruitingPhase 1/2Immunocore LtdNCT04262466Written as Brenetafusp and monoclonal antibodies and chemotherapy
- To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125CompletedPhase 1Teva Branded Pharmaceutical Products R&D, Inc.NCT02673567Written as TEV-48125 - 1
- Human Penile Tissue Allotransplantation for Devastating Penile and Concomitant Genital TraumaWithdrawnPhase 1Wake Forest University Health SciencesNCT03240822Written as Monoclonal Antibody (Humanized Anti-CD52)
- Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1CompletedPhase 3GlaxoSmithKlineNCT00678886Written as otelixizumab infusion plus physician determined standard of care
- Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)SuspendedPhase 1/2Humanigen, Inc.NCT01211691Written as KB004, Monoclonal Antibody
- First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy VolunteersCompletedPhase 1Light Chain Bioscience - Novimmune SANCT01808469Written as Monoclonal antibody
- Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's MacroglobulinemiaCompletedNot applicableDana-Farber Cancer InstituteNCT00142155Written as monoclonal antibodies
Given in every arm · 4 — Antibodies, Monoclonal is usual care beside what is tested
- Phase 1/2 Study of IMC-R117C in Selected Advanced CancersRecruitingPhase 1/2Immunocore LtdNCT06840119Written as Monoclonal antibody
- Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal CancerCompletedPhase 4Tanta UniversityNCT06115174Written as Monoclonal antibodies (target therapy)
- Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent GlioblastomaStatus unknownPhase 1Assistance Publique Hopitaux De MarseilleNCT03631836Written as Monoclonal antibody
- A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The PancreasCompletedPhase 1Hoffmann-La RocheNCT00711191Written as monoclonal antibody
As the comparator · 1 — what is tested is compared with Antibodies, Monoclonal
Codes
What other systems call Antibodies, Monoclonal · ClinicalTrials.gg INT006993
- MeSH (NLM) D000911Antibodies, MonoclonalOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000911 | Antibodies, Monoclonal | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.